Human medicines European public assessment report (EPAR): Adcetris, brentuximab vedotin, Lymphoma, Non-Hodgkin;Hodgkin Disease, Date of authorisation: 25/10/2012, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Adcetris, brentuximab vedotin, Lymphoma, Non-Hodgkin;Hodgkin Disease, Date of authorisation: 25/10/2012, Revision: 35, Status: Authorised

Human medicines European public assessment report (EPAR): Otezla, apremilast, Arthritis, Psoriatic;Psoriasis, Date of authorisation: 15/01/2015, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Otezla, apremilast, Arthritis, Psoriatic;Psoriasis, Date of authorisation: 15/01/2015, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): COVID-19 Vaccine (inactivated, adjuvanted) Valneva, COVID-19 vaccine (inactivated, adjuvanted, adsorbed), Date of authorisation: 24/06/2022, Revision: 6, Status: Withdrawn

Human medicines European public assessment report (EPAR): COVID-19 Vaccine (inactivated, adjuvanted) Valneva, COVID-19 vaccine (inactivated, adjuvanted, adsorbed), Date of authorisation: 24/06/2022, Revision: 6, Status: Withdrawn

Human medicines European public assessment report (EPAR): COVID-19 Vaccine (inactivated, adjuvanted) Valneva, COVID-19 vaccine (inactivated, adjuvanted, adsorbed), COVID-19 virus infection, Date of authorisation: 24/06/2022, Revision: 6, Status: Withdraw

Human medicines European public assessment report (EPAR): COVID-19 Vaccine (inactivated, adjuvanted) Valneva, COVID-19 vaccine (inactivated, adjuvanted, adsorbed), COVID-19 virus infection, Date of authorisation: 24/06/2022, Revision: 6, Status: Withdrawn

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.